Ali Bazarbachi, MD, PhD, American University of Beirut Medical Center, Beirut, Lebanon, discusses the evolution of outcomes over time for relapsed Hodgkin lymphoma (HL) after autologous stem cell transplantation (auto-SCT). Real-world data from 1781 HL patients in the European Blood and Marrow Transplant (EBMT) registry was analyzed to assess the prognosis of patients with recurrent-HL post-auto-SCT. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.